Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 1, 2016, Pages 45-56

  Baranska, A ^a,b   Mujagic, Z ^a,b   Smolinska, A ^a,b   Dallinga, J W ^b   Jonkers, D M A E ^b   Tigchelaar, E F ^a,c   Dekens, J ^a,c   Zhernakova, A ^a,c   Ludwig, T ^d   Masclee, A A M ^b   Wijmenga, C ^a,c   van Schooten, F J ^b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d DANONE NUTRICIA RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VOLATILE ORGANIC COMPOUND;

ADULT; ARTICLE; BREATH ANALYSIS; CASE CONTROL STUDY; CONTROLLED STUDY; EXPIRED AIR; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; SELF REPORT; SENSITIVITY AND SPECIFICITY;

EID: 84977659436     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13654     Document Type: Article

References (42)

1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71–80.
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949–58.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480–91.
4. Plavsic I, Hauser G, Tkalcic M, Pletikosic S, Salkic N. Diagnosis of irritable bowel syndrome: role of potential biomarkers. Gastroenterol Res Pract 2015; 2015: 490183.
5. Camilleri M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther 2015; 42: 818–28.
6. Sood R, Ford AC. Diagnosing irritable bowel syndrome with a combination of biomarkers and “psychomarkers”. Gastroenterology 2014; 146: 1418–20.
7. de Boer NKH, de Meij TGJ, Oort FA, et al. The scent of colorectal cancer: detection by volatile organic compound analysis. Clin Gastroenterol Hepatol 2014; 12: 1085–9.
8. Khalid T, Richardson P, Probert CS. The liver breath! Breath volatile organic compounds for the diagnosis of liver disease. Clin Gastroenterol Hepatol 2014; 12: 524–6.
9. Bodelier AGL, Smolinska A, Baranska A, et al. Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn's disease: a metabolomic approach. Inflamm Bowel Dis 2015; 21: 1776–85.
10. Kurada S, Alkhouri N, Fiocchi C, Dweik R, Rieder F. Review article: breath analysis in inflammatory bowel diseases. Aliment Pharmacol Ther 2015; 41: 329–41.
11. Arasaradnam RP, Covington JA, Harmston C, Nwokolo CU. Review article: next generation diagnostic modalities in gastroenterology–gas phase volatile compound biomarker detection. Aliment Pharmacol Ther 2014; 39: 780–9.
12. Patel N, Alkhouri N, Eng K, et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 2014; 40: 498–507.
13. Mujagic Z, Ludidi S, Keszthelyi D, et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 2014; 40: 288–97.
14. Stolk RP, Rosmalen JG, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008; 23: 67–74.
15. Tigchelaar EF, Zhernakova A, Dekens JA, et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open 2015; 5: e006772.
16. Dallinga JW, Smolinska A, van Schooten FJ. Analysis of volatile organic compounds in exhaled breath by gas chromatography-mass spectrometry combined with chemometric analysis. Methods Mol Biol 2014; 1198: 251–63.
17. Smolinska A, Hauschild AC, Fijten RR, Dallinga JW, Baumbach J, van Schooten FJ. Current breathomics – a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res 2014; 8: 027105.
18. Guyon I.A Scaling Law for the Validation-Set Training-Set Size Ratio. Berkeley, CA: AT&T Bell Laboratories, 1997.
19. Snee RD. Validation of regression models: methods and examples. Technometrics 1977; 19: 415–28.
20. Breiman L. Bagging predictors. Mach Learn 1996; 24: 123–40.
21. Esbensen KH, Geladi P. Principles of proper validation: use and abuse of re-sampling for validation. J Chemometr 2010; 24: 168–87.
22. Kruijer W, Boer MP, Malosetti M, Flood PJ, Engel B. Marker-based estimation of heritability in immortal populations (vol 199, pg 379, 2015). Genetics 2015; 200: 385.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate – a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995; 57: 289–300.
24. Hardoon DR, Szedmak S, Shawe-Taylor J. Canonical correlation analysis: an overview with application to learning methods. Neural Comput 2004; 16: 2639–64.
25. Arasaradnam RP, Westenbrink E, McFarlane MJ, et al. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis – a pilot study. PLoS ONE 2014; 9: e107312.
26. Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE 2013; 8: e58204.
27. Bodelier AGL, Smolinska A, Baranska A, et al. Volatile organic compounds in exhaled air as novel marker for disease activity in crohn's disease: a metabolomic approach. Inflamm Bowel Dis 2015; 21: 1776–85.
28. Pijls K, Smolinska A, Jonkers D, et al. A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis. Sci Rep-UK 2016; 6: 19903.
29. Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799–807.
30. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163–73.
31. Mete R, Tulubas F, Oran M, et al. The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation. Med Sci Monit 2013; 19: 762–6.
32. Phillips M, Cataneo RN, Cummin AR, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003; 123: 2115–23.
33. Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005; 6: 71.
34. Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 2007; 110: 835–44.
35. Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015; 110: 278–87.
36. Turner C, Spanel P, Smith D. A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS. Physiol Meas 2006; 27: 321–37.
37. Lindinger W, Taucher J, Jordan A, Hansel A, Vogel W. Endogenous production of methanol after the consumption of fruit. Alcohol Clin Exp Res 1997; 21: 939–43.
38. de Lacy Costello B, Amann A, Al-Kateb H, et al. A review of the volatiles from the healthy human body. J Breath Res 2014; 8: 014001.
39. Seipke RF, Kaltenpoth M, Hutchings MI. Streptomyces as symbionts: an emerging and widespread theme? FEMS Microbiol Rev 2012; 36: 862–76.
40. Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics 2012; 129: 950–60.
41. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepat 1998; 10: 59–62.
42. Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015; 42: 491–503.